Lymphocyte markers on peripheral blood lymphocytes in controls, obstructive sleep apnoea (OSA) patients without treatment and OSA patients after one night of nasal continuous positive airway pressure (nCPAP) treatment
| Markers | Controls | OSA | OSA nCPAP | 3-way p-value | Controls versus OSA p-value | Controls versus CPAP p-value | OSA versus CPAP p-value |
| CD8# | 29.5±6.6 (16) | 28.0±7.6 (31) | 28.1±6.0 (13) | ns | ns | ns | ns |
| CD16# | 13.6±5.1 (12) | 17.2±5.4 (14) | 15.0±5.1 (3) | ns | 0.11 | ns | ns |
| CD56# | 18.1±5.2 (12) | 20.2±6.8 (30) | 24.5±11 (13) | 0.2 | ns | 0.1 | ns |
| CD56bright¶ | 3.6±1.2 (7) | 6.0±1.3 (12) | 3.1±1.9 (9) | 0.002 | 0.003 | ns | 0.004 |
| CD8+/CD56++ | 35.2±11.0 (15) | 50.0±13.9 (30) | 40.7±15.2 (13) | 0.003 | 0.0007 | ns | 0.06 |
| CD8+/CD16++ | 19.1±7.6 (12) | 36.1±13.7 (12) | 0.004 | ||||
| CD8+/NKB1++ | 5.4±4.2 (11) | 5.3±4.0 (15) | 10.5±4.5 (9) | 0.03 | ns | 0.05 | 0.01 |
Data are presented as %±sd (n), unless otherwise stated. NKB1: natural killer inhibitory receptor. #: % of labelled lymphocytes; ¶: % CD56bright (mean fluorescence intensity 800–1200) among CD56+ T-lymphocytes; +: % of double-stained cells among CD8+ T-lymphocytes.